T1	intervention 0 16	Oral ibandronate
T3	intervention-participants 1038 1041	287
T4	control 1046 1053	placebo
T5	control-participants 1057 1060	277
T7	outcome-Measure 1123 1160	skeletal morbidity period rate (SMPR)
T8	outcome 1441 1450	mean SMPR
T9	iv-cont-mean 1474 1478	0.95
T10	cv-cont-mean 1482 1486	1.18
T12	outcome 1612 1636	events requiring surgery
T13	iv-cont-mean 1585 1589	0.73
T14	cv-cont-mean 1593 1597	0.98
T15	iv-cont-mean 1638 1642	0.47
T16	cv-cont-mean 1646 1650	0.53
T17	outcome 1750 1774	risk of a skeletal event
T18	condition 37 59	skeletal complications
T2	eligibility 937 984	patients with breast cancer and bone metastases
T19	outcome 1887 1899	upper GI AEs
T6	outcome 1539 1583	mean number of events requiring radiotherapy
